T. Utsugi

发表

Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362.

C. Bucana, C. Dinney, I. Fidler, 1991, Cancer research.

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

K. Anderson, N. Munshi, P. Richardson, 2014, Leukemia.

Review Article: Strategy for Drug Discovery at Pharmaceutical Companies New Challenges and Inspired Answers for Anticancer Drug Discovery and Development

T. Utsugi, 2013 .

New Challenges and Inspired Answers for Anticancer Drug Discovery and Development

T. Utsugi, 2013, Japanese journal of clinical oncology.

Tumorigenesis and Neoplastic Progression Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network

Wei Wang, S. Sone, S. Yano, 2011 .

Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state

S. Sone, T. Utsugi, M. Ogawara, 2004, Cancer Immunology, Immunotherapy.

A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state

S. Sone, T. Utsugi, M. Ogawara, 2004, Cancer Immunology, Immunotherapy.

TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice

H. Wada, K. Ikizawa, T. Utsugi, 2020, Scientific Reports.

A Dual Topoisomerase Inhibitor, TAS‐103, Induces Apoptosis in Human Cancer Cells

Yin Li, Taka-Aki Sato, Yuji Yamada, 1999, Japanese journal of cancer research : Gann.

N. Munshi, P. Richardson, M. Samur, 2017, Blood.

Scientific section designations: Lymphoid Neoplasia Title: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma Short title: TP53RK is a novel therapeutic target in myeloma

N. Munshi, P. Richardson, M. Samur, 2016 .

DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.

N. Osheroff, Yuji Yamada, J. Fortune, 1999, Biochemistry.

Identification of dominant T-cell epitopes in the major Japanese cypress pollen allergen Cha o 3.

T. Utsugi, E. Sasaki, T. Osada, 2019, Allergology international : official journal of the Japanese Society of Allergology.

Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines

Y. Aoyagi, K. Wierzba, Yuji Yamada, 2000, Japanese journal of cancer research : Gann.

Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells

Y. Rustum, C. Wrzosek, H. Minderman, 2000, Cancer Chemotherapy and Pharmacology.

In vitro Antitumor Activity of TAS‐103, a Novel Quinoline Derivative That Targets Topoisomerases I and II

Y. Aoyagi, Yuji Yamada, T. Kobunai, 1999, Japanese journal of cancer research : Gann.

Topoisomerases in Multidrug Resistance

C. Herzog, D. Fan, T. Utsugi, 1995 .

Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.

M. Mattern, C. Mirabelli, N. Hanna, 1990, Cancer research.

Differential Effects of Recombinant Interferons α, β, and γ on Induction of Human Lymphokine (IL–2)–Activated Killer Activity

S. Sone, T. Ogura, T. Utsugi, 1988 .

Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages

I. Fidler, Y. Denkins, C. Pak, 1991, Cancer Immunology, Immunotherapy.

Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.

C. Dinney, I. Fidler, A. V. von Eschenbach, 1992, Cancer research.

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

H. Hirai, Y. Nakatsuru, N. Oda, 2013 .

Synergism of recombinant human interferon gamma with liposome‐encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes

E. Shimizu, S. Sone, T. Ogura, 1986, International journal of cancer.

Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells.

S. Sone, T. Ogura, T. Utsugi, 1987, Journal of immunology.

DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.

N. Osheroff, D. Burden, J. Fortune, 1999, Biochemistry.

Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II

Y. Aoyagi, S. Okazaki, K. Wierzba, 1997, Japanese journal of cancer research : Gann.

Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.

T. Tsuruo, Y. Sugimoto, K. Wierzba, 1996, Cancer research.

Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes.

C. Bucana, I. Fidler, A. Schroit, 1991, Cancer research.

Induction of human monocyte-mediated tumor cell killing by a plant lectin, wheat germ agglutinin.

S. Sone, T. Utsugi, M. Ogawara, 1985, Japanese journal of cancer research : Gann.

Effector mechanism of human monocyte-mediated cytotoxicity: role of a new tumor cytotoxic factor distinct from interleukin 1 and tumor necrosis factorα

M. Munekata, S. Sone, T. Ogura, 1989, Biotherapy.

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

N. Munshi, P. Richardson, D. Chauhan, 2015, PloS one.

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

A. Iwama, P. Richardson, T. Hideshima, 2014, Cancer research.

[Augmentation of natural killer (NK) cell activity in human blood lymphocytes by a new synthetic acyltripeptide (FK-565) and its derivatives].

E. Shimizu, S. Sone, T. Utsugi, 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.

S. Sone, T. Utsugi, 1986, Journal of immunology.

Induction by interferon-alpha of tumoricidal activity of adherent mononuclear cells from human blood: monocytes as responder and effector cells.

S. Sone, T. Utsugi, T. Shirahama, 1985, Journal of biological response modifiers.

In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362

C. Dinney, I. Fidler, J. Killion, 1991, Cancer Immunology, Immunotherapy.

Method of quantitative analysis of ATP related compounds on the rough sea - Method of high-performance liquid chromatography using reversed-phase column.

T. Utsugi, Mutsuyosi Tsuchimoto, Tosio Misima, 1985 .

Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.

N. Hanna, T. Utsugi, S. Demuth, 1989, Cancer research.

Potentiation Enhancement of Topoisomerase Activity as a Mechanism of Breakage and Cytotoxicity by Tumor Necrosis Factor : Potentiation of Topoisomerase Inhibitor-induced DNA Strand

Christopher, M. Mattern, N. Hanna, 2006 .

Up‐ and down‐regulation of human lymphokine (IL‐2)‐activated killer cell induction by monocytes, depending on their functional state

S. Sone, T. Ogura, T. Utsugi, 1988, International journal of cancer.

Life prolonging effect of antitumor agents on postoperative adjuvant therapy in the lung spontaneous metastasis model in mice.

M. Fukushima, K. Murakami, T. Utsugi, 1998, Anticancer research.

Identification of Cha o 3 homolog Cry j 4 from Cryptomeria japonica (Japanese cedar) pollen: Limitation of the present Japanese cedar-specific ASIT.

T. Utsugi, E. Sasaki, T. Osada, 2018, Allergology international : official journal of the Japanese Society of Allergology.

Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.

S. Sone, T. Utsugi, P. Tandon, 1986, Cancer research.

Frozen-thawed human blood monocytes respond reproducibly to activation stimuli: Implications for screening of BRMs

I. Fidler, T. Utsugi, A. Nii, 1992, Biotherapy.

433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase

N. Fujita, H. Hirai, S. Mizuarai, 2014 .

398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer models

Kimihiro Ito, H. Hirai, Y. Nakatsuru, 2014 .

Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients

S. Sone, T. Ogura, T. Utsugi, 2005, Cancer Immunology, Immunotherapy.

Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .

H. Hirai, A. Miura, T. Utsugi, 2013 .

27 TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer

K. Matsuo, H. Ueno, T. Utsugi, 2014 .

Prostaglandin E2 does not inhibit tumoricidal activity of mouse macrophages against adherent tumor cells.

I. Fidler, T. Utsugi, 1991, Journal of immunology.

Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids.

K. Wierzba, T. Kobunai, T. Utsugi, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification and gene cloning of a new major allergen Cha o 3 from Chamaecyparis obtusa (Japanese cypress) pollen.

M. Okano, K. Kino, T. Utsugi, 2016, The Journal of allergy and clinical immunology.

Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents.

I. Fidler, T. Utsugi, O. Bakouche, 1990, Lymphokine research.

SAT0056 TAS5315, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR, DEMONSTRATES POTENT EFFICACY AGAINST BONE DESTRUCTION IN AN ANIMAL MODEL FOR RHEUMATOID ARTHRITIS

F. Hosoi, K. Ikizawa, Y. Arima, 2019, Poster Presentations.

G.P.88 Novel inhibitor of hematopoietic prostaglandin D synthase improves the muscle disorder in an experimental model of Duchenne muscular dystrophy

Y. Urade, T. Sasaoka, T. Utsugi, 2014, Neuromuscular Disorders.

Abstract C111: In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI.

Masanori Kato, Kimihiro Ito, Y. Iwasawa, 2013 .

In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells.

C. Dinney, I. Fidler, J. Killion, 1991, Lymphokine and cytokine research.

Advances in Brief Elevated Expression of Phosphatidylserine in the Outer Membrane Leaflet of Human Tumor Cells and Recognition by Activated Human Blood Monocytes 1

I. Fidler, A. Schroit, T. Utsugi, 2006 .

Abstract C177: TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs.

T. Abe, T. Shimomura, Koji Ichikawa, 2013 .